Use of daclatasvir in HCV/HIV-coinfected patients in a real-life setting

AIDS Reviews

Volumn 19, Issue 1, 2017, Pages 24-34

  Bonora, Stefano ^a   Puoti, Massimo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Daclatasvir; Efficacy; HCV HIV coinfection; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASUNAPREVIR; ATAZANAVIR PLUS COBICISTAT; BILIRUBIN; COBICISTAT PLUS DARUNAVIR; CYTOCHROME P450 3A INHIBITOR; DACLATASVIR; DASABUVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; MULTIDRUG RESISTANCE PROTEIN; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TENOFOVIR; TRIACYLGLYCEROL LIPASE; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

AIDS PATIENT; AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CHRONIC HEPATITIS C; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GASTROINTESTINAL INFECTION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER CIRRHOSIS; LYMPHOCYTOPENIA; MIXED INFECTION; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RELAPSE; ANTAGONISTS AND INHIBITORS; COINFECTION; DRUG INTERACTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; GENOTYPE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85012049733     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Kim AY, Chung RT. Coinfection with HIV1 and HCV—a one-two punch. Gastroenterology. 2009;137:795-814.
2. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol. 2009;83:7366-74.
3. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci. 2012;16:1473-83.
4. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis. 1994;170:1410-17.
5. Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362-71.
6. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-13.
7. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308:370-8.
8. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50:1056-63.
9. Chung RT, Andersen J, Volberding P, et al. Peginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-9.
10. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779-89.
11. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-93. Erratum, N Engl J Med. 2009;361:1027.
12. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16.
14. Poordad F, McCone J Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
15. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-28.
16. Bronowicki JP, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: the PROVIDE study interim results. J Hepatol 2012;56(Suppl 2):S6.
17. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96-100.
18. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56:3359-68.
19. EMA. Assessment report Daklinza. 26 June 2014 - EMA/419836/2014.
20. European Medicines Agency recommends approval of Daklinza in chronic hepatitis C. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/06/WC500169370.pdf (Accessed 23.02.2015).
21. FDA approves new treatment for chronic hepatitis C genotype 3 infections. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm455888.htm (Accessed 23.02.2015).
22. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236.
23. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-62.
24. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593-601.
25. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
26. Herbst DA, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs. 2013;22:527-36.
27. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368:34-44.
28. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310:804-11.
29. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49:138-47.
30. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384:1756-65.
31. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2). Hepatology. 2016;64:360-9.
32. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370:1483-93.
33. Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother. 2015;49:566-81.
34. Hezode C, Hirschfield GM, Ghesquiere W, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon-alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b AI444010 study interim week 12 results. Hepatology. 2011;54:474-5A.
35. Hezode, C, Alric L, Brown A, et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015;21:195-205.
36. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216-24.
37. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-21.
38. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63:1493-505.
39. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714-25.
40. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015;61:1127-35.
41. Mandorfer M, Schwabl P, Steiner S, et al. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease. AIDS. 2016;30:1039-47.
42. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;14:430-41.
43. Daklinza [prescribing information]. Princeton, NJ: Bristol-Meyers Squibb Company; 2015.
44. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407.
45. Eley T, You X, Wang R, et al. Daclatasvir: overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs. HIV DART, 2014, Miami. [Abstract].
46. Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor TMC-435 with HIV antiretroviral agents in healthy volunteers. Infectious Disease Society Association Conference 2012; San Diego [Abstract].
47. Poveda E, Wyles DL, Mena A, Pedreira JD, Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct‐acting antiviral agents. Antiviral Res. 2014;108:181‐91.
48. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus non-structural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54:1924-35.
49. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641-50.
50. Smith MA, Regal RE, Mohammad RA. Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016;50:39-46.
51. Kao JH, Lee YJ, Heo J, et al. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016;36:1433-41.
52. Wei, et al. 25th Conference of the Asian Pacific Association for the Study of the Liver: February 20-24, 2016 Tokyo Japan. [Oral Presentation O-050].
53. McPhee, et al. 25th Conference of the Asian Pacific Association for the Study of the Liver: February 20-24, 2016 Tokyo Japan. [Poster P-0102].
54. McPhee F, Suzuki Y, Toyota J, et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther. 2015;32:637-49.
55. McPhee, et al. 25th Conference of the Asian Pacific Association for the Study of the Liver: February 20-24, 2016 Tokyo Japan. [Poster P-709].
56. Zhou N, Han Z, Hartman-Neumann S, et al. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother. 2016 [Epub ahead of print].
57. Hezode C, Dore GJ, Pianko S, et al. Daclatasvir plus sofosbuvir plus ribavirin for 12 or 16 weeks in treatment-experienced patients with HCV genotype 3 infection and advanced fibrosis or cirrhosis. EASL 2016 [Poster SAT-129].
58. McPhee F, Hernandez D, Zhou N. Next-generation sequencing analysis of NS5A and NS5B minor resistance-associated variants in patients with HCV genotype 3 infection who failed treatment with daclatasvir plus sofosbuvir. EASL 2016 [Poster FRI-171].
59. Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596-606.
60. Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU). Available at: https://clinicaltrials.gov/ct2/show/record/NCT02368522 [Accessed 23.02.2015].
61. Rockstroh J, Welzel TM, Ingiliz P, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV: Interim results of a multicenter European Compassionate Use Program. The Liver MeetingR 2015: The 66th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, 2015. [Poster 1058].
62. Lacombe K, Fontaine H, Dhiver C, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HIV-HCV co-infection: interim analysis of a French multicenter compassionate use program. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention of Vancouver, Canada, 2015. [Oral TUAB0207LB].
63. Salmon-Ceron D, Lacombe K, Esterle L, et al. Use of oral DAA-based regimens in HIV-HCV co-infected patients in a real life setting – interim analysis from the ANRS CO13 HEPAVIH Cohort. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention of Vancouver, Canada, 2015. [Oral TULBPE09].
64. Merli M, Messina E, Morelli P, et al. Antivirali ad azione diretta per HCV nella pratica clinica: tollerabilita ed efficacia virologica in soggetti con epatopatia avanzata e co-infezione da HIV. XIV Congresso Nazionale SIMIT. Catania, Italy, 2015. [Abstract 24].
65. Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from The French Observational Cohort Anrs Co22 Hepather. International Liver Congress 2015. Vienna, Austria. [Abstract LB3].
66. Pol S, Vallet-Pichard A, Corouge M. Treatment of hepatitis C virus genotype 3-infection. Liver Int. 2014;34(Suppl 1):18-23.
67. Welzel TM, Petersen J, Ferenci P, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European Compassionate Use Program. The Liver Meeting 2015. San Francisco, 2015. [Oral abstract 37].
68. Hezode C, De Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV Genotype 3 Infection: Interim analysis of a French Multicenter Compassionate Use Program. The Liver Meeting 2015. San Francisco, 2015. [Oral abstract 206].
69. Buccoliero G, Cristiano L, Casalino G, Pisconti S, Resta F. Efficacia e sicurezza della co-somministrazione di daclatasivir 60mg e atazanavir non boosterato con ritonavir in soggetti HIV virosoppressi da lungo termine. XIV Congresso Nazionale SIMIT. Catania, Italy, 2015. [Abstract 251].
70. Colletti P, Trizzino M, Adamoli L, et al. Novel DAA regimens: real practice in a HIV/HCV coinfected and HCV mono-infected Sicilian population. XIV Congresso Nazionale SIMIT. Catania, Italy, 2015. [Abstract 260].
71. Maida I, Mori Ubaldini F, Barabino L, et al. Terapia HCV nella real practiceclinica: monitoraggio del profilo di sicurezza dei nuovi DAA. XIV Congresso Nazionale SIMIT. Catania, Italy, 2015. [Abstract 231].
72. Craxi A, Perno CF, Vigano M, et al. From current status to optimization of HCV treatment: Recommendations from an expert panel. Dig Liver Dis. 2016;48:995-1005.
73. AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org/ node/74 (Accessed 24.09.2016).